Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques

被引:0
|
作者
Davi, H
Tronquet, C
Miscoria, G
Perrier, L
Dupont, P
Caix, J
Simiand, J
Berger, Y
机构
[1] Sanofi Rech, Preclin Drug Metab & Pharmacokinet, Montpellier, France
[2] Sanofi Rech, Preclin Drug Metab & Pharmacokinet, Toulouse, France
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metabolism and disposition of irbesartan, an angiotensin II AT(1) receptor antagonist, were investigated in mice, rats, rabbits, and macaques. In both rats and macaques, irbesartan was characterized by a rapid oral absorption, a large volume of distribution, a low plasma clearance, and a long terminal half-life. The oral bioavailability in macaques was notably higher than in rats. Irbesartan was highly protein bound in rats and macaques. A lower binding rate was found in mice and rabbits. In distribution studies performed in rats, mice, and rabbits, irbesartan was rapidly distributed into most organs and tissues including brain, intrauterine area, and milk. No retention of radioactivity in tissues other than liver and kidney was noted. Irbesartan was the main circulating compound in rats, rabbits, and macaques representing a maximum of 67, 68, and 80% of plasma radioactivity, respectively. The drug was metabolized mainly by glucuronidation (primarily on the tetrazole ring), hydroxylation, and additional oxidation. The overall pathways within the different species generated 18 metabolites identified from bile, urine, and feces samples. Irbesartan did not significantly induce or inhibit most of the isoenzymes commonly associated with drug metabolism in either rats or macaques after oral administration for 1 month. In most species irbesartan and its metabolites were mainly excreted in feces with more than 80% of a radioactive dose recovered within 24 or 48 h. Enterohepatic circulation was demonstrated in rats and macaques.
引用
收藏
页码:79 / 88
页数:10
相关论文
共 50 条
  • [1] Irbesartan an angiotensin II receptor antagonist protects focal cerebral ischemia in rats
    Akhtar, M.
    Pratap, R.
    Pillai, K. K.
    Khanan, R.
    Islam, F.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 102 - 103
  • [2] Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats
    Voigt, Joerg-Peter
    Bramlage, Peter
    Fink, Heidrun
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 564 (1-3) : 131 - 137
  • [3] A review of the new angiotensin II receptor antagonist irbesartan
    Powell, JR
    Reeves, RA
    Marino, MR
    Cazaubon, C
    Nisato, D
    CARDIOVASCULAR DRUG REVIEWS, 1998, 16 (03): : 169 - 194
  • [4] Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs
    Kondo, T
    Yoshida, K
    Yoshimura, Y
    Motohashi, M
    Tanayama, S
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1996, 46 (06): : 594 - 600
  • [5] A review of the clinical experience with the angiotensin II receptor antagonist irbesartan
    Waeber, B
    CARDIOVASCULAR DRUG REVIEWS, 2000, 18 (02): : 103 - 126
  • [6] Clinical overview of irbesartan - A new angiotensin II receptor antagonist
    Pouleur, HG
    AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (12) : 318S - 324S
  • [7] Angiotensin II receptor pharmacology and AT1-receptor blockers
    Chung, O
    Csikós, T
    Unger, T
    JOURNAL OF HUMAN HYPERTENSION, 1999, 13 (Suppl 1) : S11 - S20
  • [8] Angiotensin II receptor pharmacology and AT1-receptor blockers
    O Chung
    T Csikós
    T Unger
    Journal of Human Hypertension, 1999, 13 : S11 - S20
  • [9] The angiotensin II AT1-receptor antagonist candesartan reduces infarct size in pigs.
    Jalowy, A
    Schulz, R
    Post, H
    Dörge, H
    Weidenbach, R
    Behrends, M
    Heusch, G
    FASEB JOURNAL, 1998, 12 (05): : A1114 - A1114
  • [10] Angiotensin II receptor antagonist irbesartan in the treatment of chronic heart failure
    Belousov, YB
    Upnitsky, AA
    Khanina, NY
    KARDIOLOGIYA, 2000, 40 (10) : 88 - 91